TY - JOUR
T1 - Cloning of G Protein-Coupled Opioid Receptors Using Degenerate PCR and Low-Stringency Homology Screening
AU - Grandy, David K.
AU - Zhou, Qun Yong
AU - Bouvier, Claudia
AU - Saez, Carmen
AU - Bunzow, James R.
N1 - Funding Information:
This work was supported in part by grants to DKG from NIDA (DA08562), NIDDK (DK47093), and NIMH (MH48991). The sequences of LC132 and the/z opioid receptor have been assigned GenBank accession numbers U01913 and U02083, respectively.
PY - 1995
Y1 - 1995
N2 - In summary we have described methods that we have used to clone the classical μ, δ, and κ opioid receptors and a new receptor, LC132, that based on structural arguments we predict is also a member of the opioid receptor gene family. The combination of low-stringency homology screening and degenerate PCR provides a powerful strategy for the cloning of members of this G protein-coupled receptor family. When these cloning techniques are combined with transient and/or stable expression and classical pharmacological analyses it is often possible to determine which receptor subtype is encoded by the cloned cDNA. Given the sensitivity of the molecular approaches, in particular PCR, and what has been observed for other G protein-coupled receptors that bind the same, or similar ligands, we expect that more receptor genes will be identified than were orginally predicted from earlier pharmacological data. The cloning of LC132 is a perfect example of the situation that molecular neuropharmacologists now face; that is the ability to clone and express a new receptor type whose sequence allows its inclusion within an established gene family yet whose endogenous ligand is unknown. We are confident, however, that in time the endogenous ligand for orphan receptors such as LC132 will be determined by combining expression in tissue culture with pharmacological and physiological analyses.
AB - In summary we have described methods that we have used to clone the classical μ, δ, and κ opioid receptors and a new receptor, LC132, that based on structural arguments we predict is also a member of the opioid receptor gene family. The combination of low-stringency homology screening and degenerate PCR provides a powerful strategy for the cloning of members of this G protein-coupled receptor family. When these cloning techniques are combined with transient and/or stable expression and classical pharmacological analyses it is often possible to determine which receptor subtype is encoded by the cloned cDNA. Given the sensitivity of the molecular approaches, in particular PCR, and what has been observed for other G protein-coupled receptors that bind the same, or similar ligands, we expect that more receptor genes will be identified than were orginally predicted from earlier pharmacological data. The cloning of LC132 is a perfect example of the situation that molecular neuropharmacologists now face; that is the ability to clone and express a new receptor type whose sequence allows its inclusion within an established gene family yet whose endogenous ligand is unknown. We are confident, however, that in time the endogenous ligand for orphan receptors such as LC132 will be determined by combining expression in tissue culture with pharmacological and physiological analyses.
UR - http://www.scopus.com/inward/record.url?scp=0342737853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0342737853&partnerID=8YFLogxK
U2 - 10.1016/S1043-9471(05)80035-7
DO - 10.1016/S1043-9471(05)80035-7
M3 - Article
AN - SCOPUS:0342737853
SN - 1043-9471
VL - 25
SP - 90
EP - 104
JO - Methods in Neurosciences
JF - Methods in Neurosciences
IS - C
ER -